Home
Luminex Panels
Human
Human Cell Therapy Cytokine Panel (20/25-Plex)

Human Cell Therapy Cytokine Panel (20/25-Plex)

Comprehensive multiplex cytokine monitoring for CAR-T cell therapy, cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS) research. Available in 20-plex and 25-plex configurations covering all core CRS and ICANS biomarkers from a single 25 μL sample.

20/25 TargetsHuman25 μL SampleSub-pg/mL Sensitivity

Request a Quote View Analytes

Cytokine release syndrome (CRS) is the most common serious adverse event associated with CAR-T cell therapy, affecting approximately 30–50% of recipients depending on CAR construct, tumor burden, and participant characteristics. CRS is not a single-cytokine disease — it represents a complex, amplified immune cascade involving CAR-T cell activation, myeloid cell recruitment, and endothelial dysregulation.

Creative Proteomics offers the Human Cell Therapy Cytokine Panel (20/25-Plex) based on the Luminex xMAP platform for simultaneous quantification of 20 or 25 key cytokines and chemokines from a single 25 μL sample. This panel covers the complete CRS-ICANS spectrum: CRS core mediators (IL-6, IFN-γ, TNF-α, IL-1β, IL-10, GM-CSF, IL-18), T cell effector cytokines (IL-2, IL-4, IL-5, IL-12p70, IL-13, IL-17A, IL-21, IL-22), chemokine networks (IL-8, MCP-1, MIP-1α, MIP-1β, IP-10, RANTES), immune counter-regulation (IL-1RA, IL-15), and tissue/vascular markers (VEGF-A, G-CSF).

Published data from Wei et al. (2023) in 202 CAR-T research participants demonstrated that IL-6, IL-10, IL-2, and IFN-γ each show highly significant differences between grade 0–2 and grade 3–4 CRS (all P < 0.001), while TNF-α, IL-17A, and IL-4 were not significantly different between CRS grades — highlighting the importance of broad multiplex profiling. The panel is validated for serum, plasma, and cell culture supernatants, compatible with MAGPIX, Luminex 200, and FLEXMAP 3D systems.

Panel Specifications

TechnologyLuminex xMAP

Panel Configurations20-plex or 25-plex

SpeciesHuman

Sample Volume25 μL

SensitivitySub-pg/mL

Dynamic Range4–5 logs

Assay Time3–4 hours

Complete Analyte List (20/25 Targets)

The Human Cell Therapy Cytokine Panel is available in two configurations covering key cytokines and chemokines involved in CAR-T cell therapy, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and other cell-based immunotherapies.

Core CRS and Inflammatory Panel (20-Plex)

Target	Alternative Name	Role in Cell Therapy
IL-6	Interleukin-6	Primary CRS mediator; central driver of the IL-6/IL-6R/GP130 signaling cascade; peak levels correlate with CRS severity
IFN-γ	Interferon-gamma	Master activator cytokine; triggers macrophage and monocyte activation that amplifies the CRS cytokine storm
TNF-α	Tumor necrosis factor-alpha	Early acute-phase cytokine; contributes to endothelial activation and vascular permeability during CRS
IL-1β	Interleukin-1 beta	Inflammasome-activated cytokine; drives fever and hypotension; synergizes with IL-6 in severe CRS
IL-2	Interleukin-2	T cell proliferation and activation marker; elevated during CAR-T expansion phase
IL-4	Interleukin-4	Th2 polarization indicator; associated with allergic-type infusion reactions
IL-5	Interleukin-5	Eosinophil activation and recruitment; elevated in delayed-type hypersensitivity reactions
IL-8	CXCL8	Neutrophil chemotaxis and endothelial activation; elevated in severe CRS and ICANS
IL-10	Interleukin-10	Key anti-inflammatory counter-regulator; paradoxically elevated in severe CRS as a compensatory response; strong predictor of CRS grade
IL-12p70	Interleukin-12 p70	Th1-polarizing cytokine; promotes IFN-γ production and CTL activity
IL-13	Interleukin-13	Th2 cytokine; involved in allergic inflammation and B cell class switching
IL-15	Interleukin-15	T and NK cell homeostatic cytokine; supports CAR-T cell persistence and memory formation
IL-17A	Interleukin-17A	Th17-lineage cytokine; contributes to tissue inflammation; not consistently associated with CRS severity
IL-18	Interleukin-18	Inflammasome-dependent cytokine; amplifies IFN-γ production via IL-18R signaling; elevated in macrophage activation syndrome-like CRS
IL-21	Interleukin-21	T follicular helper cytokine; promotes B cell and plasma cell differentiation
IL-22	Interleukin-22	Tissue-protective cytokine; involved in epithelial barrier maintenance during inflammatory stress
GM-CSF	Granulocyte-macrophage CSF	Key myeloid cell activator; emerging evidence suggests GM-CSF is a critical upstream amplifier of CRS via monocyte/macrophage activation
G-CSF	Granulocyte CSF	Neutrophil mobilization factor; often administered therapeutically post-CAR-T but also endogenously elevated
MCP-1	CCL2	Monocyte chemoattractant; elevated in ICANS and associated with blood-brain barrier disruption
MIP-1α	CCL3	Macrophage inflammatory protein; chemoattractant for monocytes and T cells

Extended Panel Additions (25-Plex)

Target	Alternative Name	Role in Cell Therapy
IL-1RA	Interleukin-1 receptor antagonist	Endogenous anti-inflammatory regulator; elevated as a counter-response to IL-1β surge; ratio of IL-1β/IL-1RA reflects net inflammatory balance
IP-10	CXCL10	IFN-γ-inducible chemokine; directs T cell trafficking to CNS; consistently elevated in ICANS and correlates with neurotoxicity grade
MIP-1β	CCL4	Macrophage and T cell chemoattractant; contributes to immune cell recruitment to sites of inflammation
RANTES	CCL5	Broad-spectrum chemokine recruiting T cells, monocytes, and eosinophils; implicated in CAR-T-related inflammatory amplification
VEGF-A	Vascular endothelial growth factor A	Endothelial activation and vascular permeability marker; elevated in severe CRS with capillary leak syndrome

Technical Specifications

Validated performance parameters for the Human Cell Therapy Cytokine Panel (20/25-Plex).

Platform and Assay

PlatformLuminex xMAP (MAGPIX / Luminex 200 / FLEXMAP 3D)

Panel Configurations20-plex or 25-plex

SpeciesHuman

Sample TypesSerum, EDTA/Heparin Plasma, CCS

Sample Volume25 μL (serum/plasma), 50 μL (CCS)

Assay Time3–4 hours

CustomizationExpandable up to 100-plex; custom panels available

Performance Metrics

SensitivitySub-pg/mL (varies by analyte)

Dynamic Range4–5 logs

Intra-Assay CV<10%

Inter-Assay CV<15%

Spike Recovery80–120%

Standard Curve5PL fit, R² > 0.98

Luminex vs ELISA for Cell Therapy Cytokine Analysis

Traditional ELISA requires 20–25 separate assays to cover the cytokines in this panel. Our Luminex multiplex panel quantifies all key CRS and ICANS biomarkers simultaneously in a single well.

Parameter	Luminex 20/25-Plex	Traditional ELISA (20+ assays)
Targets per Well	20–25	1
Wells Required	1	20–25
Sample Volume	25 μL	500–625 μL
Assay Time	3–4 hours	80–100 hours
Dynamic Range	4–5 logs	1–2 logs
Data Points per Sample	20–25	1
Re-dilution	Rarely needed	Often required

Sample Requirements for Cell Therapy Cytokine Luminex Assays

Proper sample collection and handling are essential for reliable cytokine measurements in cell therapy research.

Recommended Sample Types

Serum25 μL, collect in SST tubes, no hemolysis

EDTA/Heparin Plasma25 μL, clear, no fibrin

Cell Culture Supernatant50 μL, centrifuge 10,000 rpm for 10 min before use

Minimum Project SizeOne 96-well plate; smaller batches accepted with surcharge

Handling Notes

Sample Storage-80°C; avoid repeated freeze-thaw cycles

ShippingDry ice or wet ice

ReplicatesDuplicate recommended

CAR-T Study NoteStandardize collection time relative to CAR-T infusion. Typical schedule: pre-infusion, Day 0 (+4h, +8h), Day 1, Day 3, Day 7, Day 14, Day 28. For CRS research, the Day 0–7 window captures the peak cytokine period.

Choosing Your Panel Configuration: 20-Plex vs 25-Plex

The two panel configurations are designed for different research objectives. Select the configuration that best matches your study endpoints.

Core CRS Panel (20-Plex)

Covers all validated CRS biomarkers (IL-6, IFN-γ, TNF-α, IL-1β, IL-10, IL-2, GM-CSF), T cell effector cytokines, and basic chemokine markers. Ideal for CAR-T product characterization, preclinical xenograft models, and multi-timepoint CRS-focused studies. 25 μL per well.

Choose this for: CRS monitoring, in vitro CAR-T characterization

Complete CRS + ICANS Panel (25-Plex)

Adds IP-10, MIP-1β, RANTES, IL-1RA, and VEGF-A for comprehensive chemokine profiling, endothelial activation assessment, and ICANS biomarker monitoring. Enables IL-1β/IL-1RA ratio calculation. 25 μL per well.

Choose this for: CRS + ICANS studies, translational research

Custom

Expandable Configuration

Add or remove targets from our full catalog to create a bespoke panel up to 100-plex. Both 20-plex and 25-plex configurations can serve as a starting point for custom panel design. Contact us for details.

Choose this for: custom target requirements

Criterion	20-Plex	25-Plex
CRS core markers (IL-6, IFN-γ, TNF-α, IL-1β, IL-10, GM-CSF)	✓	✓
T cell effector cytokines (IL-2, IL-4, IL-5, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-22)	✓	✓
Myeloid/chemokine markers (IL-8, MCP-1, MIP-1α, G-CSF)	✓	✓
ICANS-associated chemokines (IP-10, MIP-1β, RANTES)	—	✓
Endothelial/vascular markers (VEGF-A)	—	✓
Immune counter-regulation (IL-1RA)	—	✓
Sample Volume	25 μL	25 μL
Recommended for ICANS studies	✗	✓

Not sure which configuration to choose? For studies where ICANS is not a primary endpoint, the 20-plex provides comprehensive CRS coverage. For translational research programs requiring complete CRS-ICANS immune monitoring, we recommend the 25-plex. Contact us to discuss your study design.

Cell Therapy Cytokine Panel Research Applications

The Human Cell Therapy Cytokine Panel (20/25-Plex) supports research across CAR-T development, CRS biomarker discovery, ICANS investigation, and cell therapy manufacturing.

CRS Biomarker Research

Quantify IL-6, IFN-γ, TNF-α, IL-10, and IL-2 at serial time points during CAR-T therapy. Wei et al. (2023) reported median IL-6 levels of 8.45 pg/mL in grade 0–2 CRS versus 72.5 pg/mL in grade 3–4 CRS (P < 0.001) across 202 research participants, demonstrating the utility of multiplex cytokine profiling for CRS biomarker research.

CAR-T Cell Functional Characterization

Measure cytokine release from CAR-T cells co-cultured with target tumor cells. IFN-γ, GM-CSF, and TNF-α levels in supernatants correlate with CAR-T cell activation and anti-tumor potency in vitro. GM-CSF is increasingly recognized as a critical upstream amplifier of CRS.

ICANS (Neurotoxicity) Biomarker Investigation

IP-10, MCP-1, IL-6, and IL-8 have been identified as key biomarkers associated with immune effector cell-associated neurotoxicity syndrome. The 25-plex configuration captures all ICANS-associated chemokines plus endothelial activation markers (VEGF-A), enabling simultaneous CRS and ICANS biomarker profiling.

CAR-T Manufacturing and QC

Cytokine production profiling serves as a functional characterization assay for CAR-T cell products. Consistent cytokine release patterns across manufacturing batches indicate product consistency. Multiplex panels provide batch-to-batch comparability data for quality monitoring.

Preclinical Cell Therapy Development

Evaluate novel CAR constructs, armored CAR-T cells, and next-generation cell therapies in mouse xenograft models. Cytokine panels provide pharmacodynamic readouts of in vivo CAR-T cell activity and safety profiling in preclinical settings.

Combination Immunotherapy Assessment

Monitor cytokine release profiles when CAR-T cells are combined with checkpoint inhibitors, oncolytic viruses, or bispecific antibodies. Multiplex profiling distinguishes additive, synergistic, or antagonistic effects on immune activation and identifies potential overlapping toxicities.

Deliverables and Quality Metrics

Every Luminex multiplex assay includes a comprehensive data package with full quality control documentation.

Data Package

Raw fluorescence intensities (.csv)
Calculated concentrations (pg/mL) with dilution factors applied for each of the 20 or 25 analytes
5PL standard curves for each analyte (R² > 0.98)
Full QC report (.xlsx format)

Quality Control

Standard curve: 8-point dilution series, 5PL fit, R² > 0.98
Intra-assay CV < 10% (duplicate measurements)
Inter-assay CV < 15% (across independent runs)
Spike recovery: 80–120%

Assay Performance

Duplicate sample measurements for all samples
Bridge sample control for multi-plate studies
Method summary including reagent lot numbers and instrument parameters
Detection limits per analyte reported in QC documentation

Case Study: Cytokine Monitoring for CRS Severity in CAR-T Therapy (Wei et al. 2023)

Wei Z, et al. (2023) used a Luminex multiplex cytokine assay to measure serum cytokine levels in 202 participants (62 children, 140 adults) receiving CD19-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. The study aimed to identify cytokine biomarkers associated with severe cytokine release syndrome (CRS).

Study Design

Cohort: 202 participants (62 children, 140 adults)
CAR-T: CD19-targeted CAR-T cells for relapsed/refractory B-ALL
Platform: Luminex multiplex cytokine assay
CRS Grading: 157 participants grade 0–2; 45 participants grade 3–4
Data: Peak cytokine levels reported as median (range) in pg/mL

Peak Cytokine Levels by CRS Grade (Median, pg/mL)

Cytokine	Grade 0–2 CRS (n=157)	Grade 3–4 CRS (n=45)	P-value
IL-6	8.45	72.5	< 0.001
IFN-γ	6.9	21.8	< 0.001
IL-10	4.9	13.2	< 0.001
IL-2	4.6	9.7	< 0.001
IL-17A	5.5	5.1	NS
TNF-α	4.0	4.3	NS
IL-4	3.7	4.3	NS

IL-6 by Age Group (Median, pg/mL)

Age Group	Grade 0–2 CRS	Grade 3–4 CRS	Range (max)
Children (n=62)	7.55	109.1	0.8 – 7,620
Adults (n=140)	8.7	66.1	1.2 – 14,521

Key Findings

IL-6, IL-10, IL-2, and IFN-γ showed highly significant differences between severe and non-severe CRS (all P < 0.001)
IL-4, TNF-α, and IL-17A were NOT significantly different between CRS grades — understanding which markers are informative and which are not is critical for panel design and data interpretation
Children showed higher median IL-6 in severe CRS (109.1 pg/mL) versus adults (66.1 pg/mL), though adults had the widest overall range extending to 14,521 pg/mL
A decision tree model combining cytokine data with laboratory parameters achieved high accuracy for CRS severity classification, demonstrating the value of multi-analyte approaches over single-marker monitoring

Implications for Your Cell Therapy Research

Multiplex is required: IL-6 alone is insufficient for comprehensive CRS characterization. IL-10, IL-2, and IFN-γ provide independent information about CRS biology. A 20–25 plex panel captures all key CRS biomarkers in a single assay well.
Dynamic range matters: IL-6 spans from < 1 pg/mL at baseline to > 14,000 pg/mL at CRS peak. Luminex's 4–5 log dynamic range captures this entire range without dilution — ELISA would require multiple dilutions and re-runs.
Pediatric vs. adult populations: Children may show different cytokine thresholds and dynamics during CRS. Broader panel coverage enables consistent measurement and comparison across age groups.
Negative results are informative: The finding that TNF-α and IL-4 were NOT significantly different between CRS grades is valuable — it means these markers should not be relied upon as primary CRS severity indicators despite their inclusion in many panels.
Longitudinal design is essential: Cytokine levels change rapidly post-infusion. Standardize collection time points (pre-infusion, Day 0, Day 1, Day 3, Day 7, Day 14) for accurate CRS trajectory analysis. Each research participant should serve as their own baseline.

Source: Wei Z, et al. Front Immunol. 2023;14:1273507. CC BY 4.0. DOI: 10.3389/fimmu.2023.1273507 · PMID: 37854590

Related Panels

Explore other Luminex and MSD panels available for cell therapy and cytokine research.

Human Cytokine Luminex Multiplex Panels

Targets: Custom cytokine selection
Platform: Luminex
Plex: 15 to 96-Plex

View Details

Human Inflammation Panel

Targets: IL-6, TNF-α, IL-1β, IP-10, IFN-γ
Platform: Luminex
Plex: 20 to 48-Plex

View Details

Human Chemokine Panel

Targets: CXC, CC, C, CX3C subfamilies
Platform: Luminex
Plex: Multiplex

View Details

Human TNF Family 15-Plex Panel

Targets: TNF-α, TNF-β, FasL, TRAIL, BAFF, APRIL
Platform: Luminex
Plex: 15-Plex

View Details

Human Cytokine Storm Panel

Targets: Cytokine storm-associated markers
Platform: Luminex
Plex: 21-Plex

View Details

Human Cancer Biomarker Panel

Targets: Oncology cytokines, growth factors
Platform: Luminex
Plex: Multiplex

View Details

Human Immune Checkpoint 37-Plex Panel

Targets: Immune checkpoint molecules
Platform: Luminex
Plex: 37-Plex

View Details

Human Growth Factor Panel

Targets: EGF, FGF, VEGF, HGF, PDGF
Platform: Luminex
Plex: 11-Plex

View Details

MSD Immuno-Oncology Panel

Targets: Immune checkpoint, cytokines
Platform: MSD ECL
Focus: fg/mL detection

View Details

← All Human PanelsBrowse species overview

Supporting Publications for Cell Therapy Cytokine Multiplex Assays

Selected references utilizing Luminex multiplex assays for cytokine profiling in CAR-T cell therapy and CRS research.

CRS BIOMARKERS

Wei Z, et al. (2023) Prediction of severe CRS and determination of biomarkers in B cell-acute lymphoblastic leukemia treated with CAR-T cells. Front Immunol. 14:1273507.

DOI: 10.3389/fimmu.2023.1273507

CRS PREDICTION

Teachey DT, et al. (2016) Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 6(6):664–679.

DOI: 10.1158/2159-8290.CD-16-0040

CRS KINETICS

Hay KA, et al. (2017) Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 130(21):2295–2306.

DOI: 10.1182/blood-2017-06-793141

CRS MECHANISM

Giavridis T, et al. (2018) CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 24(6):731–738.

DOI: 10.1038/s41591-018-0041-7

Customization available: Select specific targets, expand plex capacity up to 100, or optimize for unusual sample matrices. Contact us for a custom quote

Frequently Asked Questions About Cell Therapy Cytokine Panel

Common questions about our Human Cell Therapy Cytokine Panel (20/25-Plex) Luminex multiplex assay service.

Which panel configuration (20-plex or 25-plex) is best for CRS monitoring?

The 20-plex covers all core CRS biomarkers (IL-6, IFN-γ, TNF-α, IL-1β, IL-10, IL-2, GM-CSF) validated in published studies. The 25-plex adds IP-10, MIP-1β, RANTES, IL-1RA, and VEGF-A for comprehensive CRS and ICANS assessment. For research programs requiring ICANS biomarker monitoring, we recommend the 25-plex configuration. See the "Choosing Your Panel Configuration" section above for a detailed comparison.

How many cytokines should I monitor for comprehensive CRS biomarker research?

Published data from Wei et al. (2023) in 202 CAR-T recipients demonstrates that IL-6, IL-10, IL-2, and IFN-γ were all significantly different between severe and non-severe CRS, while TNF-α, IL-17A, and IL-4 were not. Monitoring a focused panel may miss informative markers; broad multiplex profiling enables unbiased identification of which markers are most informative for your specific CAR construct and research population. Our 20/25-plex panels capture all validated CRS markers plus negative controls (TNF-α, IL-17A) in a single assay.

What concentration ranges are expected for IL-6 in CAR-T therapy research?

In the Wei et al. (2023) study of 202 CAR-T recipients, median IL-6 was 8.45 pg/mL in grade 0–2 CRS versus 72.5 pg/mL in grade 3–4 CRS, with individual maximum values reaching 14,521 pg/mL in adults and 7,620 pg/mL in children. Luminex's broad dynamic range (4–5 logs) captures this entire range without re-dilution, which is critical for multi-timepoint studies where concentrations can change 1,000-fold within 48 hours.

Are TNF-α and IL-4 informative for CRS severity assessment?

Wei et al. (2023) found that TNF-α and IL-4 were NOT significantly different between CRS grades (both P > 0.05), despite their biological plausibility and inclusion in many commercially available panels. While our panel covers these markers for comprehensive immune profiling, published evidence indicates that IL-6, IL-10, IL-2, and IFN-γ are the strongest discriminators of CRS severity.

What is the role of GM-CSF in CRS pathophysiology?

GM-CSF is increasingly recognized as a critical upstream amplifier of CRS. CAR-T cell-derived GM-CSF activates monocytes and macrophages, which then produce IL-6, IL-1β, and other downstream mediators. This has made GM-CSF a focus of next-generation CAR-T engineering (e.g., GM-CSF-knockout CAR-T cells) and therapeutic intervention studies. The 20-plex includes GM-CSF alongside its downstream effectors for comprehensive pathway analysis.

How are values below the lower limit of detection (LLOD) reported?

Concentrations below the LLOD are flagged in the final report. For CAR-T studies where baseline (pre-infusion) samples may have very low cytokine levels in healthy or pre-conditioned research participants, we can recommend high-sensitivity assay configurations. Contact us to discuss expected concentration ranges for your study cohort.

Can this panel be combined with CAR-T cell monitoring by flow cytometry on the same sample?

Yes. If your study requires both soluble cytokine profiling and flow cytometry-based CAR-T cell monitoring (e.g., CAR copy number, immunophenotyping), we can coordinate a combined workflow. The small sample volume requirement (25 μL for Luminex) preserves material for complementary assays from the same blood draw.

What is the minimum project size for CRS biomarker research studies?

One 96-well plate. For multi-timepoint studies (e.g., 50 participants × 8 time points = 400 samples), we can accommodate one or multiple plates. Contact us with your expected sample schedule (number of participants, time points per participant) for optimized plate layout planning and a project-specific quotation.

Interested in a Panel?

Request a Quote

For Research Use Only. Not for use in diagnostic or clinical procedures.

Inquiry Basket